Digest Network Come funziona
Network
/
Società
Ge
Non verificato

GenSight Biologics S.A.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMercato azionarioOtticaSalute

10 comunicati stampa

Guarda tutti i comunicati
28/08/2025
Biotecnologia
Farmaceutica
Salute
Mercato azionario
Finanza
Web e Social Network
Telefonia e Varie
GenSight Biologics Postpones Release of 2025 Half-Year Financial Results
Fonte
GenSight Biologics S.A.
Emittente
Business Wire
1.00
0
08/04/2025
Biotecnologia
Salute
Farmaceutica
Ottica
GenSight Biologics Announces the Filing of its 2024 Universal Registration Document
Fonte
GenSight Biologics S.A.
Emittente
Business Wire
1.00
0
27/02/2025
Biotecnologia
Salute
Farmaceutica
Ottica
Mercato azionario
GenSight Biologics Reports Estimated Full-Year 2024 Consolidated Financial Results
Fonte
GenSight Biologics S.A.
Emittente
Business Wire
1.00
0
15/01/2025
Industria
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Ottica
GenSight Biologics Announces Publication of 5-Year Outcomes for Patients Treated Unilaterally with LUMEVOQ® Gene Therapy
Fonte
GenSight Biologics S.A.
Emittente
Business Wire
1.00
0
18/12/2024
Biotecnologia
Farmaceutica
Ottica
Salute
GenSight Biologics Provides Update on Regulatory Discussions and Financial Situation
Fonte
GenSight Biologics S.A.
Emittente
Business Wire
1.00
0
13/11/2024
Industria
Salute
Biotecnologia
Farmaceutica
Ottica
GenSight Biologics Announces Submission of LUMEVOQ® Dossier to ANSM to Prepare for Restart of Early Access Program in France
Fonte
GenSight Biologics S.A.
Emittente
Business Wire
1.00
0
28/10/2024
GenSight Biologics Announces Publication of Meta-Analyses Showing Better Outcomes for ND4-LHON Patients Treated with LUMEVOQ®
Fonte
GenSight Biologics S.A.
Emittente
Business Wire
1.00
0
24/10/2024
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Ottica
GenSight Biologics Reports Cash Position as of September 30, 2024, and Provides Business Update
Fonte
GenSight Biologics S.A.
Emittente
Business Wire
1.00
0
23/09/2024
Mercato azionario
Biotecnologia
Salute
Farmaceutica
Ottica
GenSight Biologics Reports Interim Financial Results for the First Half of 2024, Provides Business Updates
Fonte
GenSight Biologics S.A.
Emittente
Business Wire
1.00
0
23/07/2024
Biotecnologia
Farmaceutica
Ottica
Salute
GenSight Biologics Reports Cash Position as of June 30, 2024, and Provides Business Update
Fonte
GenSight Biologics S.A.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0